Jaymes Fuller

Bristol-Myers Squibb Company

Jaymes joined BMS (Celgene Cellular Therapeutics) in August of 2010 in the Developmental Quality Control group providing QC and core analytical testing support for Celgene’s allogeneic placental MSC-based cell therapy platform. Later, as part of the Analytical Research and Development organization, Jaymes led and contributed to analytical strategy and development of identity, potency, and cell vitality-based release and characterization methods across product platforms including allogeneic and autologous-based cell therapies as well as tissue-derived products. This body of work included supporting development and U.S. approval of the first-in-class BCMA-targeting CAR T cell therapy, Abecma, for the treatment of late stage multiple myeloma.

In his current role, Jaymes leads a team of scientists and engineers focused on building knowledge related to elucidation of mechanisms of action and identification of critical quality attributes for cell therapy products across BMS’ pipeline.